Subcellular membrane and granule fractions derived from human platelets contain factor VIIII antigen and von Willebrand factor activity but not factor VII procoagulant activity. Circulating platelets constitute a significant reservoir of plasma factor VIII antigen, containing approximately 15% of the amount of factor VIII antigen present in platelet-poor plasma. The antibiotic ristocetin, which...

Protein specific aptamers are highly applicable affinity ligands in different fields of research and clinical applications. They have been developed against various targets, in particular, bio-macromolecules such as proteins. Among human proteins, the coagulation factors are the most attractive targets for aptamer selection and their specific aptamers had valuable characteristics in therapeutic...

Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...

Several biological medicines derived from human and animal plasmas can effectively improve haemostasis in individuals with inherited or acquired defects in haemostasis. Factor VIII and factor VIII/vWF and factor IX concentrates are used to treat haemophilia A, von Willebrand disease and hemophilia B respectively. Cryoprecipitates are used to treat hypofibrinogenemia and von Willebrand disease w...

abstract background autologus platelet gel is easy to prepare and is relatively low cost. the aim of this study was to prepare and evaluate in vitro efficacy of autologus platelet gel. materials and methods in this experimental study, platelet concentrate and platelet poor plasma were prepared with aphaeresis method. thrombin was prepared by mixing the plasma with calcium. thrombin activity lev...

background: factor viii administration to hemophilia a patients results in an immune response (inhibitor formation) which significantly complicates the therapy. the present study was performed to determine the prevalence of inhibitor development in hemophilia a patients receiving recombinant factor viii therapy. materials and methods: this was an observational descriptive study. clotting factor...